JAM-A and ALCAM are therapeutic targets to inhibit diapedesis across the BBB of CD14+CD16+ monocytes in HIV-infected individuals.
about
Chronic Low-Grade Inflammation in Childhood Obesity Is Associated with Decreased IL-10 Expression by Monocyte SubsetsA genome-wide CRISPR screen identifies a restricted set of HIV host dependency factors.Altered Monocyte Phenotype in HIV-1 Infection Tends to Normalize with Integrase-Inhibitor-Based Antiretroviral Therapy.Soluble CD163 and monocyte populations in response to antiretroviral therapy and in relationship with neuropsychological testing among HIV-infected children.Frog Virus 3 dissemination in the brain of tadpoles, but not in adult Xenopus, involves blood brain barrier dysfunction.Human T-Lymphotropic Virus Type 1-Induced Overexpression of Activated Leukocyte Cell Adhesion Molecule (ALCAM) Facilitates Trafficking of Infected Lymphocytes through the Blood-Brain Barrier.Identification of glycoproteins associated with HIV latently infected cells using quantitative glycoproteomics.Frontline Science: CXCR7 mediates CD14(+)CD16(+) monocyte transmigration across the blood brain barrier: a potential therapeutic target for NeuroAIDS.HIV and viral protein effects on the blood brain barrier.HIV-1 Tat disrupts blood-brain barrier integrity and increases phagocytic perivascular macrophages and microglia in the dorsal striatum of transgenic mice.The inner blood-retinal barrier: Cellular basis and development.Substance P-mediated chemokine production promotes monocyte migration.Dopamine Increases CD14+CD16+ Monocyte Transmigration across the Blood Brain Barrier: Implications for Substance Abuse and HIV Neuropathogenesis.Astrocyte-shed extracellular vesicles regulate the peripheral leukocyte response to inflammatory brain lesions.Mechanisms of CNS Viral Seeding by HIV+ CD14+ CD16+ Monocytes: Establishment and Reseeding of Viral Reservoirs Contributing to HIV-Associated Neurocognitive Disorders.ALCAM (CD166) is involved in extravasation of monocytes rather than T cells across the blood-brain barrier.The Biology of Monocytes and Dendritic Cells: Contribution to HIV Pathogenesis.HIV Neuroinfection and Alzheimer's Disease: Similarities and Potential Links?In Vitro Blood-Brain Barrier Modeling adapted for Peripheral Blood Mononuclear Cell Transmigration from HIV-Positive Patients for Clinical Research on Therapeutic Drug Intervention
P2860
Q28555065-64B1DC4F-ADEF-490D-87E4-5EBA5947ED39Q33906477-2DF50660-9054-4B9D-BD46-6DF83EE237A2Q35796695-D476B63C-D96B-40A9-A3BE-F70988F401E5Q36509571-0E601FC8-CA03-49E1-A764-BBD64071112FQ36638592-5A67F75A-136F-420F-BDDB-F7B1B0B0E839Q37174479-0FBFE047-F4C8-4D90-BA28-29B9F692994FQ37383798-6FF3DFBE-50D3-4397-8C7A-DA7468310F40Q38654347-239CDE7D-0655-41FB-90C3-AFB7F11B190EQ38824376-750F7014-29FE-4D9D-BA2B-20EB7BE84BB4Q39037544-09470631-2403-4B02-9C59-208470E3540EQ39376508-27636686-7CA8-4FAA-9955-32D78EC2D936Q40268840-3B712A43-655C-45D6-8FA1-CADC296FB3FDQ40354055-3E7AA3AE-5687-4048-8634-22BEECE35D23Q41521490-A9DAB989-1C5D-4F78-A93D-521C5E4BD9FFQ42638904-0D5AE2C8-227A-40D8-8AE8-3DC3448E24DBQ49080862-5F5038B1-CECB-4415-853C-DF59DFFE0D5EQ50131761-AB395626-DE51-4328-8EE3-B5B92811A2EBQ58750745-B95C1725-26F8-4501-953A-11A42D3F337AQ58775726-66974C7D-9B02-4CA9-B6CF-DB2DD004B835
P2860
JAM-A and ALCAM are therapeutic targets to inhibit diapedesis across the BBB of CD14+CD16+ monocytes in HIV-infected individuals.
description
2014 nî lūn-bûn
@nan
2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
JAM-A and ALCAM are therapeuti ...... s in HIV-infected individuals.
@ast
JAM-A and ALCAM are therapeuti ...... s in HIV-infected individuals.
@en
type
label
JAM-A and ALCAM are therapeuti ...... s in HIV-infected individuals.
@ast
JAM-A and ALCAM are therapeuti ...... s in HIV-infected individuals.
@en
prefLabel
JAM-A and ALCAM are therapeuti ...... s in HIV-infected individuals.
@ast
JAM-A and ALCAM are therapeuti ...... s in HIV-infected individuals.
@en
P2860
P356
P1476
JAM-A and ALCAM are therapeuti ...... s in HIV-infected individuals.
@en
P2093
Joan W Berman
Kathryn Anastos
P2860
P304
P356
10.1189/JLB.5A0714-347R
P577
2014-11-24T00:00:00Z